All News
Filter News
Found 806,088 articles
-
Danaher To Present At The 38th Annual J.P. Morgan Healthcare Conference
1/9/2020
Danaher Corporation announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2020 at 8:00 a.m. PT.
-
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management ChangesTodos preparing to relocate headquarters to USA
1/9/2020
Todos Medical Ltd. announced that it has entered into an exclusive option agreement to acquire Provista Diagnostics, Inc., an in vitro diagnostics company with a CLIA/CAP certified lab in Alpharetta, Georgia, developing and commercializing the proprietary Videssa® blood test for breast cancer.
-
Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones
1/9/2020
On track to submit IND application for lead candidate, NTLA-2001 for transthyretin amyloidosis, in mid-2020 and dose first patients in 2H 2020
-
Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial
1/9/2020
Innate Pharma SA announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas.
-
T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer
1/9/2020
T2 Biosystems, Inc., a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced that its Board of Directors has appointed diagnostics industry veteran John Sperzel as President and Chief Executive Officer, effective immediately.
-
Syneos Health Announces Strategic Collaboration and Investment in Indegene Omnipresence and the Company’s Next-Generation CRM and Omnichannel Engagement SaaS Platform
1/9/2020
Omnipresence Platform Provides Biopharmaceutical Companies Advanced Analytics, AI and Cloud Innovations Powered by Microsoft
-
Clinical Analytics Leader Covera Health Closes Series B Financing Round of $23.5 Million Led by Insight Partners
1/9/2020
As the country’s leading provider of clinical analytics solutions to reduce medical misdiagnoses, Covera Health announced its Series B financing, led by Insight Partners, with participation from existing investors, including New York-based Prism Ventures.
-
NASHNET Designates Eighth Center of Excellence for Nonalcoholic Steatohepatitis
1/9/2020
Central Virginia VA Health Care System Recognized for Innovation and Care Delivery Excellence in the Care of Fatty Liver Disease [09-January-2020] NEW YORK , Jan. 9, 2020 /PRNewswire/ -- Eight leading care delivery systems from across the country have been designated as founding charter members of NASHNET and Centers of Excellence (COEs). In partnership with The Kinet
-
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
1/9/2020
Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio
-
Vericel to Present at the 22nd Annual Needham Growth Conference on Wednesday, January 15, 2020
1/9/2020
Vericel Corporation announced that Gerard Michel, CFO, will present a company overview at the 22nd Annual Needham Growth Conference in New York on Wednesday, January 15, 2020, at 12:00pm Eastern Time.
-
Neural Analytics Appoints Diane M. Bryant as Chairman and CEO
1/9/2020
Neural Analytics, Inc., a medical robotics company developing and commercializing technologies to measure and track brain health, announced it has appointed former Google Cloud COO Diane M. Bryant as Chairman and CEO, effective immediately.
-
AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa
1/9/2020
Applied Genetic Technologies Corporation reported positive interim six-month data from its ongoing Phase 1/2 clinical program in X-linked retinitis pigmentosa.
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
1/9/2020
Apellis Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.
-
Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities
1/9/2020
Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million
-
BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere.
-
FARE said the biomarker research project, which will be conducted at Janssen’s World Without Disease Accelerator, “has the potential to make a real and significant impact for the 32 million Americans living with food allergies.”
-
Researchers with Rush University Medical Center injected tumors with flu vaccines and found that this attracted immune cells to attack the tumors.
-
Synthetic biology – an engineering approach to biological science– is gaining traction in biotechnology worldwide.
-
While the research has only been conducted on mice, scientists from the university say their work is yielding positive results.
-
If one of your goals is to go for that big promotion this year, there are a few things you can do now to get the ball rolling.